Launch Africa Ventures has added Clarrio.ai, formerly known as Knowlepsy, to its Fund II portfolio in a move that underlines the growing importance of real-world data in healthcare. The investment marks a major milestone for the health tech startup, which focuses on improving outcomes for patients with chronic diseases. It also reinforces Launch Africa Ventures’ strategy of backing technology-driven companies that can scale across Africa, the Gulf region, and global markets.
Strategic Investment in Chronic Disease Data
The decision to invest in Clarrio.ai centers on one of the biggest gaps in healthcare, the shortage of high quality real world data for chronic disease management. By addressing this blind spot, Clarrio.ai is creating what is described as Africa’s first large scale chronic disease dataset. This data asset is expected to unlock new value for hospitals, insurers, and pharmaceutical companies while enabling more precise and proactive care.
Clarrio.ai's Real World Evidence Platform
Clarrio.ai is building a multimodal real-world evidence platform that aggregates data from more than 300 connected devices, electronic health records, and daily life interactions. The system combines physiological, behavioral, psychological, and environmental signals into one secure, clinically focused intelligence engine. This unified view allows healthcare stakeholders to understand how lifestyle, medication use, and clinical events interact over time.
Clinically Proven Impact on Patient Outcomes
Early results from pilot studies highlight the potential impact of the technology on patient health and quality of life. Among epilepsy patients, the platform has been associated with 34 percent fewer hospitalizations, 32 percent fewer seizures, and a 45 percent return to work rate. These clinically observed outcomes suggest that continuous monitoring and predictive analytics can reduce crises while supporting patients in resuming normal activities.
Technology, Integration, and Market Positioning
The platform is designed to be device agnostic, working with all major wearables and connected health devices used by patients in their daily lives. It integrates directly with hospital systems through FHIR and HL7 standards, ensuring that insights fit into existing clinical workflows rather than operating as a separate silo. With this approach, Clarrio.ai positions itself as an intelligence layer for chronic disease care rather than a standalone application.
Regional Focus and Growth Plans
Clarrio.ai and Launch Africa Ventures emphasize that the partnership strengthens the company’s mission across Africa, the GCC, and other international markets. The goal is to shift chronic care from a reactive model, where interventions follow acute events, to a predictive and personalized model guided by continuous data. By capturing the 98 percent of patient life that usually remains unseen by clinicians, the company aims to help healthcare providers act earlier and more effectively.
Clarrio.ai’s inclusion in Launch Africa Ventures’ Fund II portfolio underscores investor confidence in data driven models for chronic care. As the company builds what it aspires to be the world’s largest real world evidence platform for chronic diseases, it is positioned to influence how hospitals, payers, and pharmaceutical firms make decisions. If it executes on its vision, Clarrio.ai could become a category defining player in global health tech, bringing greater clarity and better outcomes to patients living with chronic conditions.